Robin Brown

Robin Brown is the Chairman of Nexus BioQuest and brings experience from nearly every sector of private healthcare innovation. He has held senior positions in biotech, big pharma, contract research and venture capital/private equity investment. Robin is currently Chairman of the Medicines Discovery Catapult and is a committee member of the UCL Technology Fund managed by Albion Capital. Recently he was CEO of KWS Biotest until its acquisition by Charles River Laboratories in 2018. Previously he spent eight years as a venture partner with Advent International. His biotechnology experience, while living in Belgium, was as CSO of Devgen (acquired by Syngenta) and Galapagos.